Introduction: Angiogenesis is the process of new blood vessels formation by capillary secretion, which during this process mature endothelial cells divides and accumulates within the new capillaries. The VGEFR / VEGF family plays an important role in regulating capillary growth. VEGF-A is the most important and well-known member of this family. Due to the mechanism of VEGF binding to its receptor, we designed a peptide based on the amino acid residues present in the receptor-binding domain of VEGF that can control angiogenesis.
Methods: subcutaneously implanted into the animals.The treatment groups received 0.5 , 2 and 10 mg/kg i.p. of the peptide daily received PBS, for twenty days. The tumor volume was measured every five days by a digital Vernier caliper, using the following formula: v= a2 × b × 0.52
Results: On last, the average tumor volume in the phosphate buffered saline (PBS)
treated group was significantly higher than in the Peptide 2 mg/kg and 10 mg/kg groups (P<0.001)
Conclusion: This peptide was able to control the rate of tumor growth when i.p injected
Keywords: Peptide design, Angiogenesis , Breast cancer, VEGFA, BALB/C